Demonstrating the Value of Personalized MedicineVideo Categories: Value
Jayson Slotnik provides an overview of the issues in demonstrating the value of personalized medicine tests and products
Dixie-Lee Esseltine, MD and George Mulligan, PhD discuss the challenges in the current standards of care of patients with multiple myeloma in the maintenance setting.
Dr Sanjiv Agarwala discusses the usefulness of MSI and TMB as novel biomarkers for various cancer types. His argument is that the first FDA approval of a therapy based on MSI rather than tumor type makes this biomarker useful, but TMB is not yet ready for “prime time.”